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H. G. Luus, N. de la Rey
Objective. The effects of multiple doses of trandolapril (a
new angiotensin-converting enzyme inhibitor) on the
pharmacodynamics of a single 25 mg dose of warfarin
were investigated in 19 men.
Design. A double-blind, placebo-controlled cross-over
design was used. The study consisted of two periods of
13 days each, during which subjects received either
trandolapril 2 mg or placebo once daily according to a
randomisation plan. Warfarin was given on day 8 of each
of these periods.
Setting. The study was carried out at the Hoechst
Research Centre for Clinical Pharmacology, Department of
Pharmacology, University of the Orange Free State,
Bloemfontein.
Patients. Nineteen healthy white men aged between 18
and 28 years and weighing between 65 and 98 kg
volunteered for the study.
Outcome measures. Prothrombin time (PT) and
coagulation factors 11, VII, IX and X were measured before
and sequentially up to 6 days after warfarin administration.
Areas under the PT and coagulation factor time curves for
warfarin + trandolapril were compared with the
corresponding areas for warfarin + placebo. The two
treatment combinations were also compared at each
measuring time.
Results. The point estimate for the ratio of the treatment
means of warfarin + trandolapril relative to warfarin +
placebo for PT was 97% (90% confidence interval: 90% -
103%). The corresponding value for factor VII was 97%
(90% confidence interval: 91 % - 102%).
Conclusion. The concomitant administration of
trandolapril did not affect the pharmacodynamic effects of
warfarin.
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Warfarin is commonly used as an oral anticoagulant and is
frequently prescribed together with other drugs. Since
warfarin has a narrow therapeutic index, its concomitant use
with other drugs may result in interference with its action
and consequent haemorrhage or spontaneous thrombosis.
The oral anticoagulants are vitamin K analogues and they
act as competitive antagonists to this vitamin at the liver
cell, thereby inhibiting the post-ribosomal step in the
synthesis of factors 11, VII, IX and X, resulting in the
formation of inactive precursor proteins.'.2 It takes at least 3
days for the full effect of vitamin K antagonism to manifest
itself since the time required for the activity of each factor to
reach steady state after commencement of therapy is -
determined by its half-life. The plasma concentration of
factor VII, which has the shortest half-life, is the first to
decrease and is followed by those of factors IX, X and 11.'
The aim of our study was to investigate the effects of
multiple doses of trandolapril, a new angiotensin-converting
enzyme inhibitor, on the pharmacodynamics of a Single dose
of warfarin. For this purpose the approach of Kroon et aJ.3
and Duursema et al.' was used. The prothrombin tlfne (PT)
and the activity of factors 11, VII, IX and X after medication
with warfarin and placebo were compared with those after
medicatipn with the warfarin and trandolapril combination.
Materials and methods
The study was approved by the Ethics Committee of the
University of the Orange Free State and the South African
Medicines Control Council and was conducted in
accordance with the guidelines of the Declaration of
Helsinki. Nineteen healthy white men aged between 18 and
28 years and weighing between 6.5 and 98 kg gave written
consent before participating in this study. They abstained
from alcohol and non-trial medication for the duration of the
study. A two-way, double-blind, randomised cross-over
design was used.
In pilot studies the inhibition of factors VII and X was
greater after an initial dose of 25 mg warfarin than after
subsequent doses 3 weeks later.' A similar observation was
also made by Stirling et al. in 1982.' For this reason a
priming dose of 25 mg warfarin alone was given to all
volunteers on day 1 of the study.
Trandolapril or placebo was given on a randomised basis
daily on days 8 through 20 and 22 through 34. The dose of
trandolapril was 2 mg and it was given under supervision
daily before breakfast at·07h30.
Warfarin sodium (25 mg) was also administered orally on
days 15 and 29, i.e. on the eighth day of treatment with
trandolapril/placebo. Factors 11, VII, IX and X activity in
plasma and the PT were measured before and 12, 24, 48,
72, 96, 120 and 144 hours after warfarin administration. The
study design is shown in Fig. 1.
Analytical methods
PT, expressed in seconds, was determined by a human
thromboplastin/calcium reagent system (Western
Diagnostics). Blood samples (4,5 ml) were collected in a
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The effects of the two treatment combinations, warfarin +
trandolapril and warfarin + placebo, on the mean PT and
factor VII concentration time profiles are illustrated in Figs 2
and 3.
CLOTTIN6 PIU'Il.E: I'Al~IN TIlE lPTJ - seconds
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Method of statistical analysis
In order to investigate the effects of trandolapril on warfarin,
the effects of treatment groups warfarin + trandolapril and
warfarin + placebo were compared by analysis of variance
of the area under the relevant clotting parameter-time data
pairs (area unde(the curve (AUC)). Point estimates and 90%
confidence intervals were calculated for the ratio of the
treatment means of warfarin + trandolapril relative to
warfarin + placebo for the areas under the curve. The same
analysis was also performed on the data at each of the
various sampling times.
3,13% w/v sodium citrate as anticoagulant. In the
laboratory, the cascade was initiated by the addition of
calcium plus the activating agent (tissue thromboplastin
which contains phospholipid and a tissue factor), and the
clotting time calculated relative to the clotting time of control
plasma treated in the same way as the test.
Factors 11, VII, IX and X were quantitatively assClyed with
an ACL coagulation instrument (Instrumentation
Laboratories) by means of the Western Diagnostics
Quantiwest 11, VII, IX and X methods"respectively. The
plasma of these types of Quantiwest reagents is deficient in
the relevant factor, but contains adequate concentrations of
the other factors necessary for coagulation. Assays are
based on a comparison of the degree of correction of the PT
of the factor-deficient plasma by the test plasma or standard
plasma. A range of dilutions of the standard and test
plasmas was prepared with Owrens Veronal buffer (pH 7),
and the PT coagulation test was performed on each sample.
The mean clotting time of each dilution of test and standard
plasma was plotted against the percentage dilution on a log-
log graph. The first dilution of the standard plasma was
regarded as equivalent to 100%. The clotting times of the
test dilutions were converted to coagUlation factor activity
by extrapolation from the test to the standard curve.
CLOTTIN6 PIU'Il.E : FACTOR VII (J)
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The mean AUC values, treatment ratios, point estimates of
the ratios and the 90% confidence intervals are given in
Table I. The results revealed that the differences between
treatments were negligible. This finding was confirmed by
Fig. 3. Factor VII activity (%) measured up to 144 hours after
medication with warfarin + placebo and warfarin + trandolapril.
Fig. 2. Prothrombin time{s} measured sequentially after
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Fig. 1. Study design.
Table I. Mean AUC values for PT and factor VII, treatment ratios, point estimates of ratios and 90% confidence intervals
Variable Treatment Mean AUC (SO) Point estimate of ratio W+T (%)
W+ P
PT W+P 134 (46,4) day.sec 97
W+T 129 (27,7) day.sec
Factor VII W+P 318 (112) %.day 97
W+T 307 (89,4) %.day
90% confidence interval (%)
90 - 103
91 - 102
w+ P = warfarin + placebo; W+T = warfarin + trandolapril.
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comparison of the treatments at each of the various
sampling times.
Changes in the activity of factors 11, IX and X were very
similar to those observed for factor VII, but since factor VII is
known to be more sensitive as an indicator of warfarin-drug
interaction, only factor VII data are presented.
Discussion
A similar approach to that of our study, i.e. a single dose of
warfarin and a multiple-dose regimen of the interacting
agent, has been used by several other investigators.3.""
However, the conflicting results obtained in some of these
studies could possibly be ascribed to the relatively small
numbers of subjects enrolled. Duursema et al.; by using 17
volunteers, showed that this model was useful for
demonstrating the effects of drugs like vitamin K (a
competitive warfarin antagonist), cholestyramine (an inhibitor
of absorption from the gastro-intestinal tract), rifampicin (a
hepatic microsomal enzyme inducer), cimetidine (a hepatic
microsomal enzyme inhibitor) and aspirin, which displaces
protein-bound drugs from their binding sites.
Our study was a pharmacodynamic one and, since the
effects of interactions between warfarin and other drugs on
coagulation factors are the important issues determining
whether haemorrhage or thrombosis will occur in the clinical
situation, warfarin plasma concentrations were not
measured.
Conclusion
By using the model described, we were able to demonstrate
the absence of a pharmacodynamic interaction between
trandolapril and warfarin. According to these results the two
compounds may safely be taken concomitantly.
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Objective. The direct urinary activity quantitation method
is quick (approximately 40 minutes), requires only a single
blood sample, is performed as part of standard renal
scanning and shows high accuracy compared With 24-
hour creatinine clearance. The purpose was to evaluate
the practical application and accuracy of this tec~niqueat
our clinic. ;
Design. Direct urinary activity quantitation was done in
patients scheduled for routine radionuclide renography
and compared to standard multiple-blood-sample
techniques by means of Cr-51-EDTA and Tc-99m-DTPA.
Setting. Academic Medical Complex, Department of
Nuclear Medicine, Universitas Hospital, Bloemfontein.
Participants. Fifteen patients scheduled for routine
radionuclide renography (glomerular filtration rate (GFR)
determination) were voluntarily enrolled in the study. The
GFRs of selected patients varied over a wide range.
Possible obstructive uropathy was excluded.
Main outcome measures. GFRs obtained by the direct
urinary method were compared with GFRs determined by
multisample Cr-51-EDTA and Tc-99m DTPA.
Results. GFRs from the direct urinary method compared
with multisample Tc-99m-DTPA showed differences from
-19,85 to 22,95 ml/min with a mean of 0,2 (:t 12,25) ml/min
(r = 0,93). When compared with multisample Cr-51 EDTA,
differences ranged from -34,35 to 21,05 ml/min with a
mean of -4,25 (:t 16,08) ml/min (r =0,90).
Conclusion. The direct urinary activity technique is
easily applied and highly accurate compared with previous
standardised multisample radionuclide techniques for
determination of GFR.
S Atr Med J 1995; 85: 770-772.
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